Blueprint Medicines Corporation (BPMC)

Market Cap	2.72B
Revenue (ttm)	204.04M
Net Income (ttm)	-557.52M
Shares Out	59.98M
EPS (ttm)	-9.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,140
Open	44.66
Previous Close	44.29
Day's Range	44.32 - 45.74
52-Week Range	37.82 - 79.40
Beta	0.69
Analysts	Buy
Price Target	70.26 (+54.54%)
Earnings Date	May 2, 2023

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRE...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2015
• Employees: 602
• Stock Exchange: NASDAQ
• Ticker Symbol: BPMC

Financial Performance

In 2022, BPMC's revenue was $204.04 million, an increase of 13.30% compared to the previous year's $180.08 million. Losses were -$557.52 million, -13.44% less than in 2021.

Analyst Forecast

According to 25 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $70.26, which is an increase of 54.54% from the latest price.

Price Target

$70.26

(54.54% upside)

Analyst Consensus: Buy